Introduction: Depression is a major public health problem. Response to selective serotonin reuptake inhibitor (SSRI) treatment varies considerably between patients. In the context of polygenic diseases like depression, measurement of a panel of biomarkers involved in the pathophysiology of depression might help predict outcome to treatment with SSRIs. Objective: The objective was to establish the relationship between serum biomarker levels and the brain-derived neurotrophic factor (BDNF) val66met polymorphism and response to SSRIs in patients with major depressive disorder. Methods: 50 patients with moderate to severe depression were recruited from the Department of Psychiatry, Sri Ra­machandra Institute of Higher Education and Research. Blood samples were collected, and Hamilton Depression Rating Scale scoring was done at baseline and after 8 weeks of treatment with SSRIs. Baseline and post-treatment levels of high-sensitivity C-reactive protein (hsCRP), BDNF and neuregulin 1β1 (NRG1β1) were analysed using commercially available ELISA kits. Genotyping of the BDNF Val66Met polymorphism was performed using a PCR-RFLP method. Results: Following treatment, there was a significant decrease in the mean hsCRP and NRG1β1 levels and a significant increase in the mean BDNF level. Responders had significantly lower baseline hsCRP and higher baseline BDNF levels when compared to non-responders. Response rates were significantly higher in the Val/Val group when compared to the Val/Met group. Conclusions: Baseline serum levels of hsCRP and BDNF predicted response to SSRIs in major depressive disorder, and Val/Val patients responded better when compared to patients carrying the Met allele.
Neuropsychobiology

中文翻译：

---

血清生物标志物水平和 BDNF 基因多态性与印度重度抑郁症患者对选择性血清素再摄取抑制剂反应的关联。

简介：抑郁症是一个主要的公共卫生问题。患者对选择性 5-羟色胺再摄取抑制剂 (SSRI) 治疗的反应差异很大。在抑郁症等多基因疾病的背景下，测量一组参与抑郁症病理生理学的生物标志物可能有助于预测 SSRIs 治疗的结果。目的：目的是建立血清生物标志物水平与脑源性神经营养因子 (BDNF) val66met 多态性和重度抑郁症患者对 SSRIs 的反应之间的关系。方法：50 名中度至重度抑郁症患者是从 Sri Ramachandra 高等教育与研究学院精神病学系招募的。收集血液样本，并在基线和 SSRIs 治疗 8 周后进行汉密尔顿抑郁量表评分。使用市售的 ELISA 试剂盒分析了高敏 C 反应蛋白 (hsCRP)、BDNF 和神经调节蛋白 1β1 (NRG1β1) 的基线和治疗后水平。使用 PCR-RFLP 方法对 BDNF Val66Met 多态性进行基因分型。结果：治疗后，平均 hsCRP 和 NRG1β1 水平显着降低，平均 BDNF 水平显着增加。与无反应者相比，有反应者的基线 hsCRP 显着较低，而基线 BDNF 水平较高。与 Val/Met 组相比，Val/Val 组的反应率显着更高。结论： hsCRP 和 BDNF 的基线血清水平预测重度抑郁症患者对 SSRIs 的反应，与携带 Met 等位基因的患者相比，Val/Val 患者的反应更好。
神经心理生物学